NCT06147544View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions

Obesity

Interventions

DRUG

PB-718

Administered subcutaneously once a week

DRUG

Placebo

Administered subcutaneously once a week

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

PegBio Co., Ltd.

OTHER